| 000 | 00881 a2200241 4500 | ||
|---|---|---|---|
| 005 | 20250513193106.0 | ||
| 264 | 0 | _c19991119 | |
| 008 | 199911s 0 0 eng d | ||
| 022 | _a0271-0749 | ||
| 024 | 7 |
_a10.1097/00004714-199910000-00001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFleischhacker, W W | |
| 245 | 0 | 0 |
_aDo phase III trials have clinical value? _h[electronic resource] |
| 260 |
_bJournal of clinical psychopharmacology _cOct 1999 |
||
| 300 |
_a391-2 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 |
_aAntipsychotic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aClinical Trials, Phase III as Topic _xtrends |
| 650 | 0 | 4 | _aHumans |
| 700 | 1 | _aHummer, M | |
| 773 | 0 |
_tJournal of clinical psychopharmacology _gvol. 19 _gno. 5 _gp. 391-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00004714-199910000-00001 _zAvailable from publisher's website |
| 999 |
_c10462651 _d10462651 |
||